title: [Four cases of therapy-related leukemia in multiple myeloma].
abstract: We have experienced 4 cases of therapy-related leukemia (TRL) in 119 patients with multiple myeloma (MM) who had received combination chemotherapy including alkylating agents between 1988 and 1998. All 4 cases were acute myelogenous leukemia, 3 were males and 1 was female. Median age at diagnosis of MM was 60 years, and median time to TRL from diagnosis of MM was 5.5 years. The chromosome abnormalities were found in 3 of those cases. All 4 cases were resistant to antileukemic chemotherapy, and median survival time from TRL was only 5.5 months. The TRL in MM is thought to be a more important problem, because recently the treatment for this disease has become more intensive, including high-dose chemotherapy supported by autologous stem cell transplantation.
authors.affiliation: Division of Hematology and Oncology, Dept. of Internal Medicine, Toho University School of Medicine.
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Natori
authors.forename: Haruka
authors.initials: H
authors.lastname: Izumi
authors.forename: Kaichi
authors.initials: K
authors.lastname: Kaneko
authors.forename: Susumu
authors.initials: S
authors.lastname: Ishihara
authors.forename: Daisuke
authors.initials: D
authors.lastname: Nagase
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Fujimoto
authors.forename: Motohiro
authors.initials: M
authors.lastname: Kato
authors.forename: Masanori
authors.initials: M
authors.lastname: Umeda
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Kuraishi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000235:genetics; D016609:Neoplasms, Second Primary / Q000209:etiology*; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D009607:Nitrosourea Compounds; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D008558:Melphalan; C020766:ranimustine; D011241:Prednisone